Ion-channel assay technologies: quo vadis?

Although many existing methods are used to study the functions of ion channels and to screen lead compounds for important ion-channel targets, new technologies are being developed for improved performance. It is important to identify the advantages and disadvantages of each technology. In this review, we segment the ion-channel assay market according to distinguishable applications, and compare the needs of each market segment with the capabilities of different technologies in terms of multiple assay attributes. We further discuss the future directions in the development of ion-channel assays.

[1]  B. Chait,et al.  The structure of the potassium channel: molecular basis of K+ conduction and selectivity. , 1998, Science.

[2]  P. Negulescu,et al.  Cell-based assays and instrumentation for screening ion-channel targets. , 1999, Drug discovery today.

[3]  A. Weston,et al.  The effects of BRL 34915 and nicorandil on electrical and mechanical activity and on 86Rb efflux in rat blood vessels , 1986, British journal of pharmacology.

[4]  Richard P. Haugland,et al.  Handbook of fluorescent probes and research chemicals , 1996 .

[5]  E. Green,et al.  A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.

[6]  Marcello Pagano,et al.  Principles of Biostatistics , 1992 .

[7]  O. Pongs,et al.  Screening lead compounds for QT interval prolongation. , 2001, Drug discovery today.

[8]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[9]  R. J. Mather,et al.  UK‐78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage‐gated potassium channel and inhibits human T cell activation , 1999, British journal of pharmacology.

[10]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[11]  F. Ponti,et al.  QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience , 2000, European Journal of Clinical Pharmacology.

[12]  W. Hanke,et al.  Planar Lipid Bilayers: Methods and Applications , 1994 .

[13]  D M Bers,et al.  A practical guide to the preparation of Ca2+ buffers. , 1994, Methods in cell biology.

[14]  B. Sakmann,et al.  Single-Channel Recording , 1995, Springer US.

[15]  Leslie M. Loew,et al.  Spectroscopic Membrane Probes , 1988 .

[16]  Clare,et al.  Voltage-gated sodium channels as therapeutic targets. , 2000, Drug discovery today.

[17]  G. Terstappen,et al.  Functional analysis of native and recombinant ion channels using a high-capacity nonradioactive rubidium efflux assay. , 1999, Analytical biochemistry.

[18]  N. Fertig,et al.  Stable integration of isolated cell membrane patches in a nanomachined aperture: a step towards a novel device for membrane physiology , 1999, cond-mat/9910217.

[19]  R Y Tsien,et al.  Improved indicators of cell membrane potential that use fluorescence resonance energy transfer. , 1997, Chemistry & biology.

[20]  Christopher Miller,et al.  Ion Channel Reconstitution , 1986, Springer US.

[21]  Florian Lang,et al.  The Use of Xenopus laevis Oocytes for the Functional Characterization of Heterologously Expressed Membrane Proteins , 2000, Cellular Physiology and Biochemistry.

[22]  M. Stern,et al.  Calcium Release Flux Underlying Ca2+ Sparks of Frog Skeletal Muscle , 1999, The Journal of general physiology.

[23]  J. Farinas,et al.  A microfluidic device for measuring cellular membrane potential. , 2001, Analytical biochemistry.

[24]  Horst Vogel,et al.  Chip based biosensor for functional analysis of single ion channels , 2000 .

[25]  Brian Cox,et al.  HTS approaches to voltage-gated ion channel drug discovery , 1998 .

[26]  L. Annunziato,et al.  Human ether-a-gogo related gene (HERG) K+ channels as pharmacological targets: present and future implications. , 1998, Biochemical Pharmacology.